APA – Approaching Support

APA is likely to find increased buying support between the $9.50 and $10.25, supported by 4.5% dividend yield and single-digit earnings growth.

About APA – Our 7,500-kilometre East Coast Grid of interconnected gas transmission pipelines provides the flexibility to move gas around eastern Australia, anywhere from Otway and Longford in the south, to Moomba in the west and Mount Isa and Gladstone in the north. In Western Australia and the Northern Territory, our pipelines stretch thousands of kilometres to supply gas to power major cities, towns and remote mining operations.

Apart from our interconnected natural gas pipelines, we own and operate the Ethane Pipeline which supplies ethane from the Cooper Basin production facility at Moomba, South Australia, to an ethylene plant in Botany, Sydney.

And it’s not just pipelines. We also own and operate the Mondarra Gas Storage and Processing Facility and the Emu Downs Wind Farm in Western Australia, Diamantina and Leichhardt Power Stations in Queensland, the Dandenong LNG Storage Facility in Victoria and the Central Ranges Gas Distribution Network servicing Tamworth in New South Wales.

Gold Road Resources – Update

Gold Road Resources is under Algo Engine buy conditions and along with NCM is our preferred gold exposure.

The company provided financial statements for the 6 month period ending June 30, which displayed revenue $135mn, EBIT, $36mn and EPS of $0.026.

Key points include:

Gold Road repaid all debt whilst retaining the undrawn facility of A$100M (US$71M). Net cash and equivalents of A$84M (US$60M) at 30 June 2020.

71,865 ounces produced* at attributable AISC of A$1,233/oz (US$875/oz)2.

Quarterly free cash flow of A$23.8M (excl. unsold bullion
and dore).

ASX – August Volumes

ASX is under Algo Engine buy conditions.

August cash equity volumes and average daily futures contract volumes were well down on the same time last year, -13% and -19% respectively.

FY21 earnings are likely to be flat at best and with the stock on a forward yield of 2.8%, we see it as “fully valued”. Owning the stock and selling an at the money covered call option is generating 8% cash flow.

We see value in buying ASX on any market weakness.

Ramsay Healthcare

Ramsay Health Care

RHC delivered 8% revenue growth in FY20, with a strong 1H more than offsetting the 4% decline experienced in 2H.

Australia suffered the greatest contraction in 2H, down 8% on the same time last year. UK revenue growth remained solid, up almost 5%.

Based on normalization in FY22 earnings, we have the stock trading on a forward yield of 2.2%.

CSL – Buy

CSL is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.

CSL & the Australian Government signed a Heads of Agreement to supply 51mn doses of the University of Queensland’s COVID-19 vaccine.

CSL & AstraZeneca also signed a Heads of Agreement for manufacture & distribution of 30mn doses of AZN’s COVID-19 vaccine (AZD1222).

We expect EPS to increase by 8 – 10% in FY21 and FY22. This supports a forward dividend yield of 1.1%.

Buy CSL within the $265 – $280 support range.